Laura M. McKay

Laura M. McKay

Auto-generated profile, based on publicly available information

Laura M. McKay

Oncology Discovery Research, AbbVie Inc., North Chicago, Illinois

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2025 in Cancer Research
Verified
Journal Article
Closed access
JSJennifer D. Stone
Jennifer D. Stone
KFKamonwan Fish
Kamonwan Fish
DADevika Ashok
Devika Ashok
LMLaura M. McKay
Laura M. McKay
SASaeed S. Akhand
Saeed S. Akhand
EREdward B. Reilly
Edward B. Reilly
NK cell–redirecting therapies are emerging as promising “off the shelf” cancer treatments with fewer safety issues compared with T cell–directed therapies. In this study, we developed ABBV-303, a c-Met–targeted multispecific NK-cell engager. ABBV-303 included three functional arms: (i) a c-Met–binding single-chain variable fragment; (ii) a Fab that binds NKG2D, a stimulatory receptor on NK cells, and activated CD8+ T cells; and (iii) a heterodimeric IgG1 Fc that binds FcγRIIIa on NK cells. ABBV-303 binding to NKG2D and FcγRIIIa redirected NK cells to lyse c-Met–expressing tumor cells and induced CD8+ T-cell activation. The treatment of peripheral blood mononuclear cells with ABBV-303 in the presence of c-Met+ tumor cells stimulated NK and CD8+ T cells as demonstrated by modulation of activation-associated surface proteins and release of soluble factors. ABBV-303 drove subnanomolar redirected killing potency against tumor cells from different solid tumor indications expressing a range of c-Met levels. ABBV-303 demonstrated antitumor activity against established xenografts in CD34-humanized, IL15 transgenic NOD/SCID-gamma mice and in a c-Met+ tumor explant. When compared with a CD3 bispecific with the same c-Met binder, ABBV-303 drove lower levels of inflammatory cytokines at equivalent levels of tumor cell killing and enhanced tolerance of normal cells expressing c-Met, consistent with the natural tendency of NK cells to preferentially react with stressed or cancer cells as compared with normal, healthy tissue. Together, this study showed that ABBV-303 is effective at driving antitumor immunity against a wide range of c-Met–expressing tumors. Significance: ABBV-303 is a biologic that engages and potently redirects NK cells and costimulates CD8+ T cells in c-Met expressing tumors while demonstrating relative tolerance of normal tissue-derived cells.

2 February 2026
Verified
Other
Open access
JSJennifer D. Stone
Jennifer D. Stone
KFKamonwan Fish
Kamonwan Fish
DADevika Ashok
Devika Ashok
LMLaura M. McKay
Laura M. McKay
SASaeed S. Akhand
Saeed S. Akhand
EREdward B. Reilly
Edward B. Reilly
NK cell–redirecting therapies are emerging as promising “off the shelf” cancer treatments with fewer safety issues compared with T cell–directed therapies. In this study, we developed ABBV-303, a c-Met–targeted multispecific NK-cell engager. ABBV-303 included three functional arms: (i) a c-Met–binding single-chain variable fragment; (ii) a Fab that binds NKG2D, a stimulatory receptor on NK cells, and activated CD8+ T cells; and (iii) a heterodimeric IgG1 Fc that binds FcγRIIIa on NK cells. ABBV-303 binding to NKG2D and FcγRIIIa redirected NK cells to lyse c-Met–expressing tumor cells and induced CD8+ T-cell activation. The treatment of peripheral blood mononuclear cells with ABBV-303 in the presence of c-Met+ tumor cells stimulated NK and CD8+ T cells as demonstrated by modulation of activation-associated surface proteins and release of soluble factors. ABBV-303 drove subnanomolar redirected killing potency against tumor cells from different solid tumor indications expressing a range of c-Met levels. ABBV-303 demonstrated antitumor activity against established xenografts in CD34-humanized, IL15 transgenic NOD/SCID-gamma mice and in a c-Met+ tumor explant. When compared with a CD3 bispecific with the same c-Met binder, ABBV-303 drove lower levels of inflammatory cytokines at equivalent levels of tumor cell killing and enhanced tolerance of normal cells expressing c-Met, consistent with the natural tendency of NK cells to preferentially react with stressed or cancer cells as compared with normal, healthy tissue. Together, this study showed that ABBV-303 is effective at driving antitumor immunity against a wide range of c-Met–expressing tumors.Significance:ABBV-303 is a biologic that engages and potently redirects NK cells and costimulates CD8+ T cells in c-Met expressing tumors while demonstrating relative tolerance of normal tissue-derived cells.

2 February 2026
Verified
Other
Open access
JSJennifer D. Stone
Jennifer D. Stone
KFKamonwan Fish
Kamonwan Fish
DADevika Ashok
Devika Ashok
LMLaura M. McKay
Laura M. McKay
SASaeed S. Akhand
Saeed S. Akhand
EREdward B. Reilly
Edward B. Reilly
Redirection of PBMCs from cancer patients by ABBV-303 to recognize c-Met + tumor cells.

2 February 2026
Verified
Other
Open access
JSJennifer D. Stone
Jennifer D. Stone
KFKamonwan Fish
Kamonwan Fish
DADevika Ashok
Devika Ashok
LMLaura M. McKay
Laura M. McKay
SASaeed S. Akhand
Saeed S. Akhand
EREdward B. Reilly
Edward B. Reilly
Activation of T cells in response to ABBV-303 within a PBMC mixture vs. purified.

2 February 2026
Verified
Other
Open access
JSJennifer D. Stone
Jennifer D. Stone
KFKamonwan Fish
Kamonwan Fish
DADevika Ashok
Devika Ashok
LMLaura M. McKay
Laura M. McKay
SASaeed S. Akhand
Saeed S. Akhand
EREdward B. Reilly
Edward B. Reilly
Impact of ABBV-303 treatment on gene expression and cytokine secretion in PBMC and c-Met + tumor cell co-cultures.

2 February 2026
Verified
Other
Open access
JSJennifer D. Stone
Jennifer D. Stone
KFKamonwan Fish
Kamonwan Fish
DADevika Ashok
Devika Ashok
LMLaura M. McKay
Laura M. McKay
SASaeed S. Akhand
Saeed S. Akhand
EREdward B. Reilly
Edward B. Reilly
Primary diagnosis, previous treatment, and current treatment information of solid tumor patients tested in Supplementary Figure 3.